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The understanding of  the human disease(s) of  diabe-
tes and its complications and of  its applicable animal 
models has considerable limitations as reflected by 
papers submitted to pharmacology-type journals and 
by discussion on various research forums. The major 
relevant areas are the aetiology and the consequences 
of  diabetes the latter being mostly cardiovascular dis-
ease and in that area there is also considerable dispar-
ity between the human disease of  atherosclerosis and 
relevant animal models [1-3]. Models are best used as 
representative of  various but specific aspects of  the 
diabetes cardiovascular disease continuum rather than 
providing a holistic approach and answers.
Diabetes is a range of  genetically and environmentally 
derived conditions diagnosed somewhat pragmatically 
on the basis on plasma glucose levels or relative hy-
perglycaemia. The current classifications of  diabetes 
cover a variety of  conditions but the two major forms 
in terms of  prevalence are Type 1 and Type 2. It is 
perhaps somewhat surprising to know that the distinc-
tion between what we now know as Type 1 and Type 
2 diabetes only became clearly apparent as recently as 
1951 when Bornstein and Lawrence published a paper 
based on studies in a newly developed hypophysecto-
mized, adrenalectomized, alloxan-diabetic rat model 
showing that plasma from patients with Type 1 diabe-
tes contained no insulin whereas that of  patients with 
what we now know as Type 2 diabetes had variable but 
substantial amounts of  insulin [4]. This lead to names 
such as Insulin- and Non-Insulin Dependent Diabe-
tes Mellitus (IDDM and NIDDM) and the awkward 
naming corollary that a patient with late stage NIDDM 
had Insulin-requiring Non-insulin Dependent Diabe-
tes Mellitus [5, 6]. After several naming iterations, dia-
betes was most recently redefined and classified by all 
the major international diabetes organisations in 1999 
– see publications on behalf  of  the American Diabetes 
Association, the European Association for the Study 
of  Diabetes, the Australian diabetes Society, the Inter-
national Diabetes Federation [7-9] – the major forms 
were classified by  Type and number – as to Type it can 
be type or Type but as to number the 1999 classifica-
tions are specifically 1 and 2 and not I and II (the use 
of  “I” and “II” and expressions such as Non-insulin 
Dependent Diabetes Mellitus thus refer to classifica-
tions before 1999). To expand briefly on the aetiology, 
Type 1 diabetes is an immunological disease resulting 
from a chronic immunological attack on the insulin-
secreting beta cells of  the pancreas and in its clinical 
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manifestation usually a very rapid decrease in the abil-
ity to produce insulin – this results in a rapid onset 
dramatic hyperglycaemia – glucose levels may reach 
40 – 50 mM precipitating polyuria and potentially life-
threatening dehydration requiring hospitalisation and 
stabilisation. Type 2 diabetes in the majority of  cases 
(approximately 80 per cent) arises from increased obe-
sity driving increasing insulin resistance due to unde-
fined mechanisms thought to be lipophilic metabolites 
inhibiting insulin signalling [10]. The insulin resistance 
can persist for a considerable time (“pre-diabetes”) 
[9], during which plasma glucose is not elevated but 
early stages of  complications are developing [11]. The 
early stages of  insulin resistance and Type 2 diabetes 
are associated with increasing insulin secretion and 
somewhat normal blood glucose levels with perhaps 
excursions under stresses such as post-prandial. So 
the early phase of  Type 2 diabetes is characterised by 
hyperglycaemia and hyperinsulinemia (refer below to 
comments on Streptozotocin (STZ) and Type 2 dia-
betes). After a prolonged period of  insulin resistance, 
glucolipotoxicity towards pancreatic beta cells induces 
pancreatic insufficiency (relative insulin deficiency) 
and a decompensation phase resulting in hyperglycae-
mia i.e. the occurrence of  hyperglycaemia (“diabetes”) 
requires a reduced capacity to secrete insulin [1, 12, 
13]. There is a substantial subset of  people with Type 
2 diabetes who are lean and in this situation the disease 
occurs due to glucolipotoxicity (in contrast to the im-
mune toxicity of  Type 1 diabetes) of  beta cells and a 
failure to secrete sufficient insulin leading to hypergly-
caemia [14]. Although this beta cell toxicity state might 
be compared to the use of  STZ in animal models this 
is not the major and common form of  Type 2 diabetes 
which is dependent upon insulin resistance and later 
insulin insufficiency.
Others have reviewed the properties of  various mod-
els of  “diabetes” but the properties of  the individual 
models should be compared against the natural his-
tory, aetiology and pathology described above [15-17] 
– individual models are best considered for the com-
ponent of  the pathological condition of  diabetes that 
they best represent and not an overall model of  diabe-
tes – indeed the definitions apply to human disease and 
animal models should be referred to as animal models 
and not as animals having the human disease. Similarly, 
the outcomes of  studies to reduce hyperglycaemia or 
to prevent the consequences of  the hyperglycaemia 
should be stated explicitly for the specific activity with 
careful extrapolation to the human disease(s). 
What of  the consequences of  diabetes? The diagnostic 
criterion is hyperglycaemia but the pathological con-
sequences almost certainly arise from a multitude of  
factors in addition to hyperglycaemia [18-23]. Some of  
these factors may be related to the diabetes such as low 
HDL cholesterol levels but others such as hyperten-
sion may be mechanistically unrelated co-morbidities 
[22, 24]. There are two considerations – the impact of  
hyperglycaemia on cardiovascular pathology and the 
impact of  treatment in reducing the disease process 
[12, 23, 25]. The two major parameters are the extent 
of  hyperglycaemia and also the duration of  the hyper-
glycaemia – hyperglycaemia has an acute effect of  ves-
sels such as on the endothelium (endothelial dysfunc-
tion) but later persistent effect on the vascular smooth 
muscle. Both small vessel microvascular disease and 
larger vessel macrovascular disease are positively cor-
related with increasing hyperglycaemia [12, 25]. The 
relationship is steeper for microvascular disease than 
macrovascular disease – this indicates that microvas-
cular disease arises from hyperglycaemia but that other 
factors are involved in the pathology of  macrovascular 
disease. Accordingly, reducing hyperglycaemia has pro-
found effects on reducing microvascular disease [12, 
25]. Treatment of  hyperglycaemia and reducing mac-
rovascular disease is a very controversial area – few 
medical interventions can be shown to reduce cardio-
vascular events based on targeting hyperglycaemia and 
even for positive studies the effects are generally so 
small as to not impact on overall survival; in compari-
son,  the effects are not nearly as strong or consistent 
as, for example, the efficacy of  statins in lowering plas-
ma cholesterol and reducing cardiovascular events [12, 
25, 26].  Furthermore, diabetes (hyperglycaemia) ap-
pears to have effects on the cardiovascular system such 
that the longer the duration of  the hyperglycaemia the 
more difficult it becomes to reverse the effects and 
obtain improved cardiovascular outcomes. The low ef-
ficacy of  some anti-hyperglycaemic drug treatment in 
patients with well-established Type 2 diabetes lead to 
suggestions that earlier intervention was required.  
The same parameters which relate to the use of  ani-
mal models on studies of  diabetes also relate to the 
study of  the macrovascular complications of  diabetes 
– there is overwhelming evidence that the time of  on-
set is shortened and the rate of  progression of  athero-
sclerosis is considerably enhanced in people with Type 
2 diabetes [11, 18]. However, it has been extremely 
difficult to produce animal models which reproduce 
this pathological response with a high degree of  fidel-
ity [27, 28]. This perhaps relates to an understanding 
of  the aetiology of  atherosclerosis in humans versus 
animal models [3, 29-32]. In an analysis of  the factors 
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precipitating atherosclerosis in humans and relevant 
rodent models it was concluded: “Finally, the mech-
anism of  disease initiation and progression are quite 
different between mice and humans, with the former 
being a macrophage-rich disease and the latter occur-
ring in a smooth-muscle-cell-rich environment with 
an extracellular matrix rich in proteoglycans, collagen, 
and entrapped lipids with sheets of  calcification”  [3]. 
In animal models of  hyperglycaemia, the inflamma-
tory phase is enhanced and accelerated [33, 34] but 
this type of  inflammatory response is a late and vari-
able response in humans [3]. Thus, not only has this 
inflammation has been very difficult to prevent in ani-
mal models the nature of  its contribution to human 
atherosclerosis is problematical. 
At the next level there are many studies based on ap-
plying high glucose concentrations to cardiovascular 
cells such as endothelial and vascular smooth muscle 
cells [35-37] and the biochemical mechanisms caus-
ing the vascular complications of  diabetes have been 
reviewed [38, 39]. Studies have been conducted with 
glucose concentrations of  40 mM or higher [40-43]. 
The highest blood glucose concentrations observed 
in even poorly medically treated patients with diabe-
tes are around 20 mM (other than people with Type 
1 diabetes at the time of  diagnosis). Despite the basic 
requirement of  science that effects are dose or con-
centration dependent very few studies provide glucose 
dose response relationships; further it is necessary to 
account for the possible osmotic effect of  raising glu-
cose concentration and the effect of  adding glucose 
(d-glucose or dextrose) to cells should, be compared 
to the effect of  adding metabolically inert l-glucose, or 
sodium chloride or mannitol or other suitable agents. 
Even the manner in which these solutions are prepared 
can determine the results of  some experiments – in 
our laboratory we have observed  different responses 
[36] from preparing elevated glucose solutions by mix-
ing low and high solutions compared to adding sterile 
concentrated glucose solutions to low glucose media 
– the reasons for this phenomena remain unknown. 
Life spans in developed countries have been increasing 
over the last several decades due to reduced childhood 
deaths, improved nutrition, reduced cigarette smoking 
and improved treatment of  hypertension and hyperlip-
idemia. However, the recent societal trends of  reduced 
physical activity, increased sedentary time, and exces-
sive energy intake are driving increased rates of  obesity 
and diabetes leading to increased cardiovascular and a 
multitude of  other diseases. If  this trend continues, as 
it appears at present, then a coming generation may 
experience a shorter life expectancy than the preced-
ing generation as well as experiencing the devastating 
morbidity associated with chronic metabolic illness. So 
in this setting the need for research in this area is pro-
found – what is required is a consolidation of  existing 
research methodologies and a quantum shift forward 
in animal models of  diabetes and its complications. 
In summary, research covering the addition of  5+ mM 
(up to say 25 mM) glucose to cell cultures called diabe-
tes research or STZ treated rodents called Type 1 dia-
betes research or STZ treated rodents on high fat diet 
and referred to as a Type 2 diabetes model is experi-
mentally valid in its own right but it is suggested that 
the extrapolations to the mentioned clinical entities 
are too great and do not reflect the clinical complex-
ity of  diabetes as outlined in brief  above. Additionally 
the types of  diabetes are specifically clinical diagnosis 
of  disease in humans. So, some caution is warranted 
in presenting research in this area when most studies 
represent a component, for example hyperglycaemia, 
rather than a complete clinical entity. 
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